|
|
Post by dreamboatcruise on Feb 27, 2018 20:10:13 GMT -5
Could be wrong but thought I heard Mike say they have two term sheets for international deals, one of which will likely be announced in the first half of 2018. Hopefully before May calls  Also that upfront or milestone payments are included which he would know if he has term sheets in hand. For those who aren't familiar, a term sheet is simply a brief outline of a deal agreed to by both parties to use to negotiate final details. There's no rule-of-thumb on how long it might take to go from term sheet to contract. It could be days, weeks or months. Regardless, this was good news. I thought he said upfront AND milestone. Will need to listen again. If it's OR I'll be disappointed. That mention of upfront was the highlight of the call in my opinion, so hope it doesn't go poof with an "or". |
|
|
|
Post by dreamboatcruise on Feb 27, 2018 20:13:45 GMT -5
I have listened to a lot of these calls for a lot of years and IMO this was the best I have heard. I think today marks a turning point for the company. The biggest news I heard on the call was they found the 60+ studies which Al Mann did and Dr. Kendall not only read them but is putting a plan together to release them. That is huge. While he did not say it I suspect these studies had a great deal to do with why Dr. Kendall came to MNKD. Al left no stone un-turned and concluded afrezza should be the standard of care for all T2s from the first day they are diagnosed. If only I had a nickle for every turning point we've had with this company. |
|
|
|
Post by mytakeonit on Feb 27, 2018 20:25:50 GMT -5
I'm waiting to see what comes out of the Brazil partnership as far as dollars go.
|
|
|
|
Post by sayhey24 on Feb 27, 2018 20:34:29 GMT -5
I have listened to a lot of these calls for a lot of years and IMO this was the best I have heard. I think today marks a turning point for the company. The biggest news I heard on the call was they found the 60+ studies which Al Mann did and Dr. Kendall not only read them but is putting a plan together to release them. That is huge. While he did not say it I suspect these studies had a great deal to do with why Dr. Kendall came to MNKD. Al left no stone un-turned and concluded afrezza should be the standard of care for all T2s from the first day they are diagnosed. If only I had a nickle for every turning point we've had with this company. This is my first so I will put a nickel in my piggy bank. Even right after approval it was a let down when they couldn't finalize the first deal and ended up signing with Sanofi. Having Dr. Kendall is a game changer. Having Dr. Kendall having all the studies and having read all the studies is huge. I was talking with a M&A biochemist at a major BP the day prior to Dr. Kendall joining. She totally dismissed afrezza sighting the 171 & 175 studies. Who could blame her. The next day it was announced Dr. Kendall took the job and all of a sudden she wanted to know more about afrezza. If she can now see what Al knew I think she too will soon be saying afrezza should be the standard of care. |
|
|
|
Post by buyitonsale on Feb 27, 2018 21:40:01 GMT -5
They just added 3 years to my time horizon  Oh well... Go MNKD! |
|
|
|
Post by bones1026 on Feb 27, 2018 21:41:35 GMT -5
I’m still trying to figure out why the date change for CC? Run and tell Wall Street we beat by .01...I loved the fact that we didn’t miss badly, but came out of cc feeling more confused than anything..Kendall is the one piece that nobody could put a negative spin on..really think HE is the “golden goose”...but the guidance provided Mike was not that I had envisioned with Dr K coming on board
|
|
|
|
Post by digger on Feb 27, 2018 22:04:56 GMT -5
what exactly is the deal with CVS that Mike was talking about? A deal with the Pharmacy Benefit Management arm of CVS (Caremark). Means they've agreed on pricing, rebates, etc. Now they have to go to the insurers that use Caremark and convince them to add Afrezza to their formularies. That's my read FWIW. It would be nice if MNKD provided some details. Having a deal doesn't mean it's a good deal. |
|
|
|
Post by derek2 on Feb 27, 2018 22:26:22 GMT -5
Anybody catch this? Not mentioned on the call. Page 51 of the 10-K
Looks like a new ATM agreement.
Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co.
On February 27, 2018, we entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”), as sales agent, pursuant to which we may offer and sell, from time to time, through Cantor Fitzgerald, shares of our common stock having an aggregate offering price of up to $50.0 million or such other amount as may be permitted by the Sales Agreement (the “ATM Offering”). The shares will be offered and sold pursuant to our shelf registration statement on Form S-3 (File No. 333-210792).
|
|
|
|
Post by moeperkins2000 on Feb 27, 2018 22:36:40 GMT -5
Just some exposure period, doesn't mean a revenue stream.
|
|
|
|
Post by sellhighdrinklow on Feb 27, 2018 22:43:02 GMT -5
I’m still trying to figure out why the date change for CC? Run and tell Wall Street we beat by .01...I loved the fact that we didn’t miss badly, but came out of cc feeling more confused than anything..Kendall is the one piece that nobody could put a negative spin on..really think HE is the “golden goose”...but the guidance provided Mike was not that I had envisioned with Dr K coming on board IMHO, Kendall is the second golden goose. the first golden goose is the STAT study which Kendall is obviously aware of the results. it was alluded to in the call that after the STAT study results are announced, there will be more focus on Type 1. Two golden geese make for a perfect marriage and sweet golden eggs to come. IMHO. the next funds raise will be small in anticipation of the STAT results at ADA in June . At that point 20 million shares will be sold at $10++ to fill Mankind's bank. JMHO based on 3 years of Afrezza use and my personal STAT study. |
|
|
|
Post by morfu on Feb 27, 2018 22:58:08 GMT -5
Using the numbers from this call:
Afrezza net revenue was $6.4 million for the six months ended December 31, 2017.
Net cash used in operating activities was [..] $53.3 million
Also, the cumulative sales reported in liane's table was about 10.3mil$ higher in 12/29/17 than 6/30/17, which gives a rough conversion factor between sales and revenue of slightly above 60%...
Should allow to make an estimate as of what Symphony-TRx we need:
There is a factor of about 8 between these numbers... and eyeballing a 350TRx/week average for these 6 months (and ignoring the increasing pricing)
So I am guessing we can expect some stock market optimism if the TRx/week gets above 1000 with some other revenue (Brazil??) and we might be close to green numbers once we hit 2000 (and some other revenues Brazil, other markets/products)
Hmm still some way to go, but no reason not to be optimisitc about it!
|
|
|
|
Post by dreamboatcruise on Feb 27, 2018 23:51:59 GMT -5
Hmmmm... am I mistaken or was nothing said about RLS this time?
|
|
|
|
Post by lakers on Feb 28, 2018 0:09:15 GMT -5
MannKind's (MNKD) CEO Michael Castagna on Q4 2017 Results - Earnings Call Transcript $MNKD www.seekingalpha.com/article/4151494We also believe will be fine with our deal for covenance of minimum of $25 million at the end of Q1 there are numerous sources of capitals we continue to look out and continue to look Afrezza product revenue, the ATM, we could bring a co-promote partner there adept options as well as our equity and international licensing as well as partnerships on the pipeline assets. Brazil remains on track, we've been having positive interactions with a partner and we expect to be able to launch there as earliest as Q1 2019. Additionally, we have a fine term sheet for a large market outside U.S. and in the process of finalizing a second term sheet. One of both is we hope to announce in the first of this year but as you know, these things take time. We do expect these deal structures will have a combination of upfront milestones royalties and more importantly we need to continue to serve patients around the world - well we know these markets may not generate a lot of cash, they will tremendously make a difference for society, and I believe with the 80 million to 100 million people in some of these markets, who haven't [indiscernible] just a minor share in these segments will offset a tremendous difference in people's lives. Slide 30 of investors.mannkindcorp.com/static-files/76875d41-2743-4a29-a76a-bc00f6d1ea33Identifies India+UAE having 80M-100M PWD. Avg A1C = 10. That’s one term sheet. It could be Cipla. Another term sheet for a large market outside U.S. could be China. Nearly 12% or 114 million Chinese adults are suffering from diabetes according to Slide 30. AMPH has first right of refusal. Slide 7. Three positive interactions w/FDA: EpiHale, TreT & Afrezza Label update – Advanced the pipeline with the filing of TreT IND to start Phase 1 Who came up with the term EpiHale? |
|
|
|
Post by mnkdfann on Feb 28, 2018 0:14:55 GMT -5
I take it the "Unidentified Company Representative" hired from Eli Lilly speaking throughout the presentation was David Kendall? LOL. |
|
|
|
Post by babaoriley on Feb 28, 2018 1:36:49 GMT -5
I have listened to a lot of these calls for a lot of years and IMO this was the best I have heard. I think today marks a turning point for the company. The biggest news I heard on the call was they found the 60+ studies which Al Mann did and Dr. Kendall not only read them but is putting a plan together to release them. That is huge. While he did not say it I suspect these studies had a great deal to do with why Dr. Kendall came to MNKD. Al left no stone un-turned and concluded afrezza should be the standard of care for all T2s from the first day they are diagnosed. Where were these 60 studies, with the Dead Sea Scrolls? |
|
Also that upfront or milestone payments are included which he would know if he has term sheets in hand. For those who aren't familiar, a term sheet is simply a brief outline of a deal agreed to by both parties to use to negotiate final details. There's no rule-of-thumb on how long it might take to go from term sheet to contract. It could be days, weeks or months. Regardless, this was good news. 
